Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year (y) study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 135 sites in South India (Bangalore, Chennai, Coimbatore, Hyderabad, Kerala, and Vijayawada) included 2354 participants (mean [SD] baseline [BL] age: 51.4 [9.2] y, T2D duration: 8.4 [5.5] y and A1C: 8.1% [1.6]). At BL, most were insulin-naïve (n=1665; 70.8%), mainly on OADs (n=1638; 69.6%). At 3 y, 1149 (57.8%) participants were on OADs only, while 806 (40.5%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 2184/2353 [92.8%] and 3 y: 1853/1988 [93.2%]). Basal insulin usage increased from BL (n=335; 14.2%) to 3 y (n=465; 23.4%). A decrease in mean (SD) A1C (-0.6 [1.7] %), FPG (-18.0 [60.3] mg/dL), and PPG (-30.3 [81.5] mg/dL); and an increase in those with A1C<7% (BL: 414 [24.5%]; 3 y: 440 [30.1%]), was noted. MI and neuropathy were the most common macro and microvascular complications, respectively (Table). The rate of microvascular complications (n, %) was highest in South India (519, 22.1%) vs. West (252, 18.8%), North (243, 14.4%) and East (107, 12.7%) at 3 y. Hypertension and dyslipidemia were the most common CV risk factors. There is need to further evaluate diabetes management strategies employed in South India to achieve optimal glycemic control.
H. Thacker: Other Relationship; Merck Sharp & Dohme Corp., Novartis India, Sanofi. K. Kumar: None. A.K. Das: Other Relationship; Sanofi. B. Ramanathan: None. A.K. Asirvatham: None. M. Shunmugavelu: None. M.D. Mruthyunjaya: None. C. Selvan: None. V. Sundaram: None. E. Philip: Other Relationship; Sanofi, Novo Nordisk, Eris Lifesciences Ltd. Research Support; Sun Pharmaceutical Industries Ltd. S.K. Menon: Employee; Sanofi. A. Gadekar: None. D. Chodankar: Employee; Sanofi.
Sanofi
